About this medicine

Brexpiprazole is an atypical antipsychotic. The checked UK product is Rxulti, used for schizophrenia in adults and adolescents aged 13 years and over. Treatment aims to reduce symptoms and help maintain stability; improvement may take days to weeks, so early follow-up matters.

This article describes the UK product, its benefits and its risks. Rexulti is retained as a cross-regional search alias, not a second verified UK brand. The presence of a medicine in a regulator's register does not establish local NHS funding, a preferred treatment position or pharmacy stock.

What is this medicine used for?

The UK SmPC's indication is schizophrenia in adults and adolescents aged 13 years and older. It does not include adjunctive treatment of depression or agitation associated with Alzheimer's disease. Information about uses in another country's product label must not be presented as a UK authorisation.

Use outside this named indication is an off-label clinical decision, requiring its own evidence and rationale. A UK marketing authorisation, a guideline recommendation and an NHS funding decision answer different questions. This product review makes no claim that every NHS service offers Rxulti.

The current MHRA category list includes all six Rxulti strengths as Category 1 products. MHRA's UK-wide arrangements apply from January 2025 and retain existing PLGB numbers; the letters GB in these identifiers are not by themselves evidence of a current exclusion of Northern Ireland.

Which warning signs need help?

Urgent assessment is needed for fever with marked muscle stiffness, sweating or altered awareness, which can indicate neuroleptic malignant syndrome. Severe allergic swelling, a seizure, chest pain or breathlessness, a swollen painful leg, or severe muscle pain or weakness with dark urine also needs urgent medical help.

New thoughts of self-harm or suicidal behaviour require prompt help, especially early in treatment or after switching. Serious hyperglycaemia, severe infection associated with low white blood cells, and fainting or abnormal heart rhythm are further important risks. Contact emergency services where the person actually is when there is immediate danger.

Brexpiprazole can cause tardive dyskinesia: involuntary movements that may persist or appear after stopping. Report new movements promptly. New gambling, compulsive shopping, binge eating or sexual urges should also be reported; the person and, with permission, a carer may notice different changes.

Use in older people with dementia is not recommended. Antipsychotics are associated with increased mortality in this group, and cerebrovascular risks require attention. These are UK product precautions; an American boxed-warning designation is not being relabelled as an MHRA warning.

How do I take it safely?

The verified UK products are Rxulti film-coated tablets containing 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg or 4 mg. They are taken by mouth, with or without food. The tablet strength is not the same as the daily dose; the prescription and supplied leaflet determine which tablets to take.

For adults, the SmPC starts at 1 mg once daily on days 1–4, followed by 2 mg on days 5–7, with a possible increase to 4 mg on day 8 according to response and tolerability. For adolescents aged 13 years and over, it starts at 0.5 mg on days 1–4, then 1 mg on days 5–7 and 2 mg on day 8; later increases are in 1 mg steps at weekly intervals when appropriate.

The usual target range is 2–4 mg daily. Moderate to severe renal impairment or hepatic impairment reduces the recommended maximum to 3 mg daily. CYP2D6 status and interacting medicines require additional changes; strong CYP3A4 inducers have a separate specialist adjustment schedule that can exceed the usual range. These reference schedules are not instructions to start, double or adjust a dose independently.

Switching antipsychotics needs a written prescriber plan. The product information distinguishes switching into Rxulti from switching away from it and accounts for its slow elimination. Do not infer a tablet-for-tablet conversion, or assume that splitting or crushing these tablets is suitable without a pharmacist checking the product.

What side effects should I know about?

Common effects include akathisia, an uncomfortable inner restlessness with an urge to move, as well as weight gain, dizziness, tremor, sleepiness, nausea, diarrhoea, upper abdominal pain and rash. These can resemble symptoms of illness, so describing when they started helps the treatment team distinguish the causes.

Blood tests can show increased prolactin or creatine kinase; a laboratory change does not automatically mean a person has symptoms or a serious complication. The leaflet gives the full adverse-effect list. Adolescents also need active review for nausea, sleepiness, restlessness and metabolic effects.

Tell the team about new persistent involuntary movements, sexual or menstrual changes, breast symptoms or difficult-to-control urges. There may be a need to reassess treatment rather than simply adding another medicine.

Who needs extra care with this medicine?

Allergy to brexpiprazole or a tablet ingredient is a contraindication. Extra care is needed with heart or cerebrovascular disease, a personal or family history of QT prolongation, electrolyte disturbance, low blood pressure, dehydration, seizures, previous movement reactions, diabetes or risk factors for blood clots.

People with a history of low white blood cells or medicine-induced neutropenia need particular attention. Swallowing difficulties, risk of aspiration and problems regulating body temperature also matter. Heat, dehydration and sedating medicines can increase practical risks.

The tablets contain lactose. The SmPC restricts use in rare hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption. Safety and efficacy for schizophrenia in people aged 65 and over have not been established; the product does not supply a minimum effective and safe dose for this group.

Can it affect my other medicines?

Strong CYP2D6 inhibitors, such as fluoxetine or paroxetine, and strong CYP3A4 inhibitors, such as clarithromycin, ritonavir or itraconazole, can increase exposure. The SmPC generally calls for half the usual dose with either strong inhibitor and a quarter with specified combined inhibitors or poor-metaboliser combinations. Exact changes require the prescriber to check the full table.

Strong CYP3A4 inducers, including rifampicin, carbamazepine, phenobarbital and St John's wort, can lower exposure. Starting or stopping them has delayed effects that can take at least two weeks to develop or decline. Their specialist adjustment instructions must not be simplified to a universal four-milligram maximum or a self-directed dose increase.

Alcohol should be avoided according to the patient leaflet. Sedatives, opioids, blood-pressure medicines, QT-prolonging medicines and medicines affecting electrolytes may add risks. Give the clinician or pharmacist a complete list of prescribed, non-prescription and herbal products, including recent changes.

What check-ups will I need?

Follow-up should assess symptoms, functioning, treatment response, adherence and unwanted effects. The SmPC advises weight monitoring, baseline and subsequent lipid assessment, and fasting glucose before or soon after starting and periodically during treatment. The clinical team sets the practical schedule.

Assess movement symptoms, restlessness and impulse-control changes, and review blood pressure on standing in people at increased risk. Heart history, other medicines and electrolyte risks guide decisions about ECGs and additional checks. Prolactin-related symptoms should prompt review.

A history of low white blood cells or medicine-induced neutropenia calls for frequent blood counts during the first months. This is a risk-based product precaution, not a claim that Rxulti has clozapine's mandatory blood-monitoring system. Review kidney or liver impairment and interactions whenever treatment changes.

What about pregnancy, breastfeeding and age?

Brexpiprazole is not recommended during pregnancy in the checked SmPC. Pregnancy plans and contraception should be discussed with the treating team. Exposure in the third trimester can cause neonatal movement or withdrawal symptoms, including feeding or breathing difficulties, and babies may need observation.

It is not known whether brexpiprazole passes into human breast milk. A decision about breastfeeding and treatment needs to weigh the benefits for the mother and child; animal milk findings are not proof of a known amount in human milk. Human fertility effects have not been studied.

The UK indication includes schizophrenia from age 13, with a different starting schedule from adults. Safety and efficacy below 13 have not been established and no data are available. Older adults need the separate caution described above; an adolescent licence does not supply a dose for younger children.

What if I miss a dose or want to stop?

The leaflet advises taking a missed dose when remembered unless the next dose is nearly due, without doubling. If two or more doses are missed, contact the doctor. The restart plan may depend on the interruption and other treatment changes.

Do not stop simply because symptoms have improved: they may return. Agree stopping or switching with the prescriber. The medicine's long elimination means exposure declines gradually, and symptoms or adverse effects after a change still need follow-up.

Suspected overdose requires urgent medical advice even if the person initially feels well. Take the medicine packaging to the treating service if practical; this article does not provide a home-treatment or taper schedule.

How does it work?

Brexpiprazole acts at receptors, proteins that receive chemical messages from other nerve cells. It partly activates dopamine D2 and serotonin 5-HT1A receptors while blocking serotonin 5-HT2A receptors; the letters and numbers identify receiving-site types, and 5-HT means serotonin. Partial activation is called partial agonism, and means a smaller receptor response than a full activator produces under comparable conditions.

The response in a living brain also depends on the surrounding chemical messages and connected cells. This combination of actions is thought to contribute to benefit, but it does not predict exactly who will improve. These actions also do not demonstrate a simple dopamine shortage or excess in an individual.

How does it affect my body?

Effects extend beyond psychotic symptoms. Restlessness, sleepiness, movement symptoms, weight gain and changes in glucose or blood lipids can affect daily life. Alpha-adrenergic effects and other factors can contribute to dizziness or fainting on standing, especially when starting or increasing treatment.

Prolactin can rise, and some people develop troublesome impulse-control behaviours. The overall response therefore includes functioning, unwanted effects and the person's experience, rather than symptom improvement alone. Avoid driving or machinery if alertness, balance or judgement is impaired.

How does my body process it?

Oral bioavailability is about 95%, with peak blood concentrations around four hours after a dose. Most circulating brexpiprazole is protein-bound. Food does not require a different administration schedule for the checked film-coated tablets.

CYP3A4 and CYP2D6 enzymes are important in metabolism. The SmPC gives a terminal half-life of about 91 hours and says steady state is reached in roughly 10–12 days. Effects of a dose change, an interacting medicine or stopping treatment can therefore evolve over several days; the drug does not disappear immediately.

Kidney or liver impairment and CYP2D6 poor-metaboliser status can alter exposure and change the recommended dose. These figures describe groups studied for the product and are not a personalised clearance calculator.

How do treatment options differ?

Brexpiprazole shares dopamine partial-agonist pharmacology with some other antipsychotics, but receptor affinity, effective doses, age licences and unwanted effects differ. A similar mechanism does not make the products interchangeable.

The SmPC describes placebo-controlled schizophrenia studies and relapse-prevention evidence. These do not establish that Rxulti is the best choice for every person or superior to every alternative. A useful comparison considers previous response, movement and metabolic effects, interactions, the person's preferences and the actual local treatment options.

A closer look at the science

The SmPC reports high affinity at D2, 5-HT1A and 5-HT2A receptors and antagonism at alpha-1B and alpha-2C adrenergic receptors. Affinity describes binding in experimental systems; it is different from the strength of the receptor response and does not establish clinical superiority over another medicine.

The tablet contains the active ingredient brexpiprazole plus formulation ingredients, including lactose. Its main circulating metabolite, DM-3411, does not appear to contribute materially to therapeutic effects on the basis of the product's preclinical exposure findings. Molecular properties do not establish an equivalent dose of another antipsychotic.

How was this medicine developed?

The checked SmPCs record first authorisation on 26 May 2023 and a text revision of 14 August 2025. The current patient leaflet is dated April 2025. These are document-specific dates, not an inferred worldwide launch date or a promise that every pack is marketed.

All six products appear in MHRA's Category 1 workbook covering authorisations in effect on 19 August 2026. UK-wide licensing arrangements retain the PLGB identifiers. The product index's legacy GB territory label must therefore be interpreted alongside the current category listing and official licensing guidance.

Earlier research located a positive regulatory listing but could not retrieve the full UK product documents. This profile uses the original SmPCs and leaflet now retrieved through the ordinary public MHRA index, rather than treating missing search results as proof that brexpiprazole is unlicensed.

Sources and References

  1. Rxulti 0.25 mg film-coated tablets: UK Summary of Product Characteristics

    Scope: United Kingdom; authorisation number retains PLGB prefix.

  2. Rxulti 0.5 mg film-coated tablets: UK Summary of Product Characteristics

    Scope: United Kingdom; authorisation number retains PLGB prefix.

  3. Rxulti 1 mg film-coated tablets: UK Summary of Product Characteristics

    Scope: United Kingdom; authorisation number retains PLGB prefix.

  4. Rxulti 2 mg film-coated tablets: UK Summary of Product Characteristics

    Scope: United Kingdom; authorisation number retains PLGB prefix.

  5. Rxulti 3 mg film-coated tablets: UK Summary of Product Characteristics

    Scope: United Kingdom; authorisation number retains PLGB prefix.

  6. Rxulti 4 mg film-coated tablets: UK Summary of Product Characteristics

    Scope: United Kingdom; authorisation number retains PLGB prefix.

  7. Rxulti 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg film-coated tablets: patient leaflet

    Scope: United Kingdom.

  8. UK-wide licensing for human medicines

    Scope: United Kingdom, including Northern Ireland.

  9. Category lists of products following implementation of the Windsor Framework

    Scope: United Kingdom.

  10. MHRA Category 1 product list: Rxulti authorisations

    Scope: United Kingdom.

  11. Rexulti (brexpiprazole): prescribing information — mechanism explanation

    Scope: Mechanism explanation only. Source sections checked: 12.1 Mechanism of Action; 12.2 Pharmacodynamics; 12.3 Pharmacokinetics. This does not establish UK product authorisation or prescribing..

  12. Tardive dyskinesia: MedlinePlus Medical Encyclopedia
  13. NIMH: Mental Health Medications
  14. A qualitative investigation into the effects of akathisia - Health Research Authority
  15. Extrapyramidal side effects- Management
  16. Anxiety and panic attacks - NHS
  17. Agitation: MedlinePlus Medical Encyclopedia

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top